# EDGAR Filing Document

**Accession Number:** 0001438569
**File Stem:** 0001104659-26-033917
**Filing Date:** 2026-3
**Character Count:** 4362
**Document Hash:** c6b8c60c16c5e34f607d82da70b80366
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-033917.hdr.sgml**: 20260324

**ACCESSION NUMBER**: 0001104659-26-033917

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260324

**FILED AS OF DATE**: 20260324

**DATE AS OF CHANGE**: 20260324

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Grifols SA
- **CENTRAL INDEX KEY:** 0001438569
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35193
- **FILM NUMBER:** 26787157

**BUSINESS ADDRESS:**
- **STREET 1:** 1585 BROADWAY
- **STREET 2:** SUITE 2376
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036
- **BUSINESS PHONE:** 212-969-3335

**MAIL ADDRESS:**
- **STREET 1:** 1585 BROADWAY
- **STREET 2:** SUITE 2376
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10036

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of March 2026**

**Commission File No. 001-35193**

**Grifols, S.A.**

(Translation of registrant's name into English)

**Avinguda de la Generalitat, 152-158**

**Parc de Negocis Can Sant Joan**

**Sant Cugat del Valles 08174**

**Barcelona, Spain**

(Address of registrant's principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ⌧ Form 40-F ◻

**Grifols, S.A.**

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| **Item** | **Item** | **Sequential Page Number** |
| [1.](#har_001) | [<u>Inside Information Note</u>](#har_001) | [3](#har_001) |

---

---

| | |
|:---|:---|
| ![](tm269714d1_6kimg001.jpg) | **Grifols, S.A.** |
| ![](tm269714d1_6kimg001.jpg) |  |
| ![](tm269714d1_6kimg001.jpg) | Avinguda de la Generalitat 152-158 |
| ![](tm269714d1_6kimg001.jpg) | 08174 Sant Cugat del Vallès |
| ![](tm269714d1_6kimg001.jpg) | Barcelona - ESPAÑA |
| ![](tm269714d1_6kimg001.jpg) |  |
| ![](tm269714d1_6kimg001.jpg) | Tel. [34] 935 710 500 |
| ![](tm269714d1_6kimg001.jpg) | Fax [34] 935 710 267 |
| ![](tm269714d1_6kimg001.jpg) |  |
| ![](tm269714d1_6kimg001.jpg) | www.grifols.com |

---

Pursuant to the provisions of article 226 of the Law 6/2023, of March 17, on Securities Markets and Investment Services, Grifols S.A. ("**Grifols**" or the "**Company**") hereby informs about the following

**INSIDE INFORMATION**

Grifols reports that, as a consequence of Grifols' self-sufficiency programs\* for its Biopharma businesses, its Board of Directors has decided to initiate a process to evaluate a potential Initial Public Offering ("**IPO**") in the United States of a portion of the shares of its subsidiary and parent of its U.S. Biopharma business.

Any such transaction remains subject to, among other things, regulatory and legal requirements, internal approvals and market conditions. There can be no assurance that any IPO will be undertaken or completed by the company.

Regardless of any such IPO being undertaken or completed, Grifols will continue to trade in Spain through the automated information system (*mercado continuo*).

This communication and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States or any other jurisdiction. No offer or sale of securities would be made absent registration under the Securities Act in compliance with the relevant U.S. securities laws.

---

| |
|:---|
| In Barcelona, 24 March 2026. |
| Laura de la Cruz Galán |
| Secretary to the Board of Directors |

---

\* Territories capable of supplying themselves with medicines derived from plasma without need of external supply.

**<u>SIGNATURES</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

---

| | | |
|:---|:---|:---|
| Grifols, S.A. | Grifols, S.A. | Grifols, S.A. |
| By: | /s/ David I. Bell | /s/ David I. Bell |
|  | Name: | David I. Bell |
|  | Title: | Authorized Signatory |

---

Date: March 24, 2026